This article is more than 5 years old. Information may no longer be current.
IOP reduced after stent implantation, postoperative prostaglandin analogue
Click Here to Manage Email Alerts
SAN FRANCISCO — Implantation of a suprachoroidal stent and use of postoperative topical travoprost may reduce IOP in phakic open-angle glaucoma patients who have uncontrolled IOP while on two topical ocular hypotensive medications, according to a presenter here.
"Following stent implantation, IOP and medication burden were significantly lowered in the absence of significant adverse events," Jonathan S. Myers, MD, said in a poster presented at the American Glaucoma Society annual meeting.
The prospective study of 80 patients was conducted by the MIGS Study Group. The iStent supra (Glaukos) was implanted with travoprost prescribed postoperatively.
Forty-two patients have been followed for 12 months postoperatively, and 98% of these patients had a 20% reduction in IOP with a reduction of one medication. Best corrected visual acuity was improved or maintained in 40 patients compared with preoperative BCVA. After 12 months, 81% of eyes had BCVA of 20/40 or better.
Also at 1 year, all patients had IOP of 18 mm Hg or less, with 90% of eyes at 15 mm Hg or less.
Disclosure: Myers consults for and receives research support from Glaukos.